This led to the initiation of our previously reported ‘first in human’ double-blind randomised placebo controlled single escalating dose phase I/IIa trial of the homologue of BiP/GRP78, now called IRL201805 [7] in RA (RAGULA trial). This evidence concerns the gene HSPA5 and rheumatoid arthritis.